- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03250806
Early Detection of Aortic Stenosis in the Community During Flu Vaccination (FluClinic)
February 11, 2020 updated by: Institut für Pharmakologie und Präventive Medizin
Early Detection of Aortic Stenosis in the Community: Role of Clinical and Echocardiographic Screening During Influenza Vaccination Multi-center, Prospective, Observational Cohort Study
Prospective cohort study to test the hypothesis that patients identified with severe aortic stenosis are under-diagnosed and under-treated.
Such patients shall be identified by auscultation or target echocardiography during flu vaccination.
The hypothesis is that this will increase detection of aortic stenosis in the community.
Study Overview
Status
Completed
Conditions
Detailed Description
The design plans for two study phases:
- Feasibility study: screening by auscultation and target echocardiography during flu vaccination in a single practice in Birmingham;
- Screening study: multi-centre screening by auscultation or target echocardiography in geographically diverse general practices across the United Kingdom.
In each phase, the patient will be identified by auscultation and target echocardiography. Management and onward referral will be at the clinical discretion of the GP. Results of clinical review, investigation, follow-up and management will be recorded at 3 months from that date.
Study Type
Observational
Enrollment (Actual)
167
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Birmingham, United Kingdom, B27 7AL
- Swanswell Medical Centre
-
-
Buckinghamshire
-
Milton Keynes, Buckinghamshire, United Kingdom, MK3 7QU
- Whaddon Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients identified on auscultation or target echocardiography with aortic stenosis.
Consecutive patients per centre with no limit to numbers.
Description
Inclusion Criteria:
- Adults aged over 65years attending for influenza vaccination.
- written informed consent to data collection
Exclusion Criteria:
- known aortic stenosis
- previous aortic valve repair/replacement
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
newly identified aortic stenosis
Patients identified on auscultation or target echocardiography with aortic stenosis.
Consecutive patients per centre with no limit to numbers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence of aortic stenosis
Time Frame: From date of examination until follow-up after three months
|
Determination of the prevalence of aortic stenosis detected on screening performed during flu vaccination.
|
From date of examination until follow-up after three months
|
comparison of detection rate of aortic stenosis
Time Frame: From date of examination until follow-up after three months
|
Comparison of detection rates of aortic stenosis using target auscultation vs detection by target 2D echocardiography.
|
From date of examination until follow-up after three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of qualitative estimation of calcium burden on 2D echocardiography as a marker of AS severity
Time Frame: three months
|
Method evaluation
|
three months
|
Calculation of costs in screening with auscultation versus target 2DE in screening for AS to inform future cost-efficacy studies of screening for AS.
Time Frame: three months
|
Cost evaluation
|
three months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Richard Steeds, MD, Queen Elizabeth Hospital, Birmingham, UK
- Study Chair: Peter Bramlage, MD, IPPMed UK Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2017
Primary Completion (Actual)
November 30, 2017
Study Completion (Actual)
November 30, 2017
Study Registration Dates
First Submitted
March 1, 2017
First Submitted That Met QC Criteria
August 11, 2017
First Posted (Actual)
August 16, 2017
Study Record Updates
Last Update Posted (Actual)
February 12, 2020
Last Update Submitted That Met QC Criteria
February 11, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FluClinic
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting